Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?
作者信息
Kouroupi E, Kiladjian J-J, Dosquet C, Menot M-L, Bonnin N, Ades L, Vainchenker W, Chomienne C, Cassinat B
出版信息
Blood Cancer J. 2012 May;2(5):e70. doi: 10.1038/bcj.2012.15. Epub 2012 May 4.
Abstract
摘要
相似文献
1
Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?提高JAK2V617F检测的灵敏度是否能识别出更多骨髓增殖性肿瘤患者？
Blood Cancer J. 2012 May;2(5):e70. doi: 10.1038/bcj.2012.15. Epub 2012 May 4.
2
[Clinical Analysis of 208 Patiets with BCR/ABL Negative Myeloproliferative Neoplasms].208例BCR/ABL阴性骨髓增殖性肿瘤患者的临床分析
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Feb;27(1):159-164. doi: 10.7534/j.issn.1009-2137.2019.01.025.
3
JAK2V617F mutation prevalence on Chilean adults suffering from primary mesenteric and portal venous thromboses.智利原发性肠系膜和门静脉血栓形成成年患者 JAK2V617F 突变的流行率。
Int J Lab Hematol. 2020 Jun;42(3):331-334. doi: 10.1111/ijlh.13184. Epub 2020 Mar 10.
4
Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.骨髓增殖性肿瘤患者 P2Y(12) 途径功能缺陷的临床和实验室意义：一项初步研究。
Acta Haematol. 2013;130(3):181-7. doi: 10.1159/000348413. Epub 2013 Jun 8.
5
The JAK2V617F Point Mutation Increases the Osteoclast Forming Ability of Monocytes in Patients with Chronic Myeloproliferative Neoplasms and Makes their Osteoclasts more Susceptible to JAK2 Inhibition.JAK2V617F点突变增加了慢性骨髓增殖性肿瘤患者单核细胞的破骨细胞形成能力，并使他们的破骨细胞对JAK2抑制更敏感。
Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018058. doi: 10.4084/MJHID.2018.058. eCollection 2018.
6
Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.CXCL-10在JAK2V617F突变的骨髓增殖性肿瘤中的细胞自主表达。
J Cancer Res Clin Oncol. 2017 May;143(5):807-820. doi: 10.1007/s00432-017-2354-1. Epub 2017 Feb 23.
7
How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?JAK2V617F如何导致骨髓增殖性肿瘤的发病机制？
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):268-76. doi: 10.1182/asheducation-2014.1.268. Epub 2014 Nov 18.
8
Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.血栓形成和出血在JAK2V617F等位基因负荷高的骨髓增殖性肿瘤患者中很常见。
Ann Hematol. 2017 Aug;96(8):1297-1302. doi: 10.1007/s00277-017-3040-8. Epub 2017 Jun 6.
9
Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.骨髓增殖性肿瘤患者JAK2V617F突变与血栓形成的相关性研究
Genet Mol Res. 2016 Aug 29;15(3):gmr8423. doi: 10.4238/gmr.15038423.
10
Single nucleotide polymorphism (SNP)-based loss of heterozygosity (LOH) testing by real time PCR in patients suspect of myeloproliferative disease.应用实时 PCR 对疑似骨髓增殖性疾病患者进行基于单核苷酸多态性（SNP）的杂合性缺失（LOH）检测。
PLoS One. 2012;7(7):e38362. doi: 10.1371/journal.pone.0038362. Epub 2012 Jul 2.
引用本文的文献
1
Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera.羟基脲和干扰素-α对真性红细胞增多症红细胞黏附及膜蛋白表达的影响。
Haematologica. 2018 Jun;103(6):972-981. doi: 10.3324/haematol.2017.182303. Epub 2018 Mar 29.
本文引用的文献
1
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.费城阴性经典骨髓增殖性肿瘤：来自欧洲白血病网络的关键概念和管理建议。
J Clin Oncol. 2011 Feb 20;29(6):761-70. doi: 10.1200/JCO.2010.31.8436. Epub 2011 Jan 4.
2
Is the JAK2(V617F) mutation detectable in healthy volunteers?健康志愿者中能否检测到JAK2（V617F）突变？
Am J Hematol. 2010 Apr;85(4):287-8. doi: 10.1002/ajh.21627.
3
Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients.应用高分辨率熔解曲线法检测真性红细胞增多症患者 JAK2 外显子 12 突变的实验室间开发和验证。
PLoS One. 2010 Jan 26;5(1):e8893. doi: 10.1371/journal.pone.0008893.
4
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.JAK2和MPL突变对内脏静脉血栓形成诊断和预后的影响：241例报告
Blood. 2008 May 15;111(10):4922-9. doi: 10.1182/blood-2007-11-125328. Epub 2008 Feb 4.
5
Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism.在未经选择的初发无诱因静脉血栓栓塞患者中，JAK2 V617F突变的发生率较低。
J Thromb Haemost. 2008 Jan;6(1):203-5. doi: 10.1111/j.1538-7836.2007.02811.x. Epub 2007 Oct 22.
6
Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.骨髓增殖性肿瘤的分类与诊断：2008年世界卫生组织标准及即时诊断算法
Leukemia. 2008 Jan;22(1):14-22. doi: 10.1038/sj.leu.2404955. Epub 2007 Sep 20.
7
The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors.在健康供者的外周血中可检测到极低水平的JAK2V617F突变。
Leukemia. 2006 Sep;20(9):1622. doi: 10.1038/sj.leu.2404292. Epub 2006 Jun 15.
8
Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.伴有V617F JAK2酪氨酸激酶突变的慢性嗜中性粒细胞白血病。
Haematologica. 2005 Dec;90(12):1696-7.
Zotero 插件